I am the Co-founder and CEO of KPL ApS, where I work alongside talented team to drive the vision and strategic direction of the company. Our focus is on advancing protein design and production to meet the evolving needs of the proteomics market. Together, we align our research and development efforts with the latest market demands to support the growth and commercialization of our innovative solutions.In addition to my role at KPL, I continue to work as a research consultant at the Novo Nordisk Foundation Center for Protein Research. With over 15 years of experience in proteomics, I have worked across multiple disciplines, utilizing mass spectrometry-based technologies to investigate cellular signaling, receptor tyrosine kinases, and post-translational modifications. My current research focuses on developing novel proteomics methodologies to rapidly identify drug targets and on creating new enzymes for proteomics applications.I remain actively engaged in collaborations throughout the Copenhagen area and frequently contribute to scientific writing, including research articles, reviews, and grant applications. My published work can be viewed here: NCBI Profile.https://www.ncbi.nlm.nih.gov/pubmed/?term=Tanveer+batth